In work presented at the 2023 European Hematology Association Meeting, Feng and colleagues used BGB-16673 to treat various TMD8-derived lymphoma cell lines, each bearing either wildtype BTK or any one of the reported mutated BTK’s that are associated with BTKi resistance (e.g. V416L, A428D, M437R, T474I, T474L, M477I, C481S, C481F, C481Y, or L528W) [14]. Here, BTK is linked to lymphoma.